India's Biocon sees oral insulin partner by March
(For other news from the Reuters India Investment Summit, click here)
BANGALORE Nov 23 (Reuters) - Biocon Ltd, India's largest listed biotechnology company, expects to find a deep-pocketed global partner for its experimental oral insulin pill by end-March, its top executive said on Wednesday .
"We are in advanced discussions with potential partners," Biocon's Managing Director Kiran Mazumdar-Shaw told the Reuters India Investment Summit in Bangalore.
In January, Biocon had said it was looking for a partner after its oral insulin, IN-105, failed to meet the main goal of an Indian late-stage trial in patients with type-2 diabetes.
Mazumdar-Shaw, however, declined to name any potential partners.
She also said the planned IPO of its contract research organisation, Syngene, was on track.
(For summit blog: blogs.reuters.com/summits/)
(For more on the Reuters India Investment Summit, see ) (Reporting by Anand Basu, Jochelle Mendonca and Aftab Ahmed in Bangalore. Editing by Sriraj Kalluvila, Saumyadeb Chakrabarty)
- Tweet this
- Share this
- Digg this
- SPECIAL REPORT - In the land of the holy cow, fury over beef exports
- GMR, Megawide group set to win Philippine airport contract
- Supreme Court turns the clock back with gay sex ban
- BSE Sensex marks biggest single-day fall in 3 weeks
- GMR picks Citi, three others for $300-$350 million airport IPO - sources
The Sensex is forecast to scale new highs next year after elections, attracting offshore funds despite an expected rough period for emerging markets when the Fed shifts monetary policy, a Reuters poll showed. Full Article
Amount of dirty money leaving developing world jumped 14 pct in 2011 - report. Full Article